Cargando…
Assessment of current virotherapeutic application schemes: “hit hard and early” versus “killing softly”?
Over the past two decades, a considerable amount of oncolytic vector families has entered numerous clinical trials. However, to this date, the field has not yet been able to come to a common understanding regarding the best possible ways to administer oncolytic viruses to cancer patients. This is ma...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782955/ https://www.ncbi.nlm.nih.gov/pubmed/27119110 http://dx.doi.org/10.1038/mto.2015.18 |